Author: IQ TIMES MEDIA

Adam Mosseri’s multimillion-dollar pay package took center stage on Wednesday as lawyers sought to link Meta’s profits to platforms that addict children.As the first of several tech executives to testify in a social media addiction trial playing out in Los Angeles state court, the head of Instagram said he is paid roughly $900,000 a year and receives annual performance-based bonuses that can be as high as half of his salary.Like many executives of publicly traded social media companies, Mosseri, who’s been head of Meta’s Instagram since 2018, also earns stock-based compensation.From the witness stand, Mosseri said that his stock-based pay…

2026-02-11T23:23:45.994Z Share Copy link Email Facebook WhatsApp X LinkedIn Bluesky Threads lighning bolt icon An icon in the shape of a lightning bolt. Impact Link Save Saved Read in app This story is available exclusively to Business Insider subscribers. Become an Insider and start reading now. Have an account? Log in. Salesforce CEO Marc Benioff made jokes about ICE during a keynote at an employee event. The company posted a recording of the keynote without Benioff’s ICE remarks. The comments drew criticism from many employees, including executives. A recording of Salesforce CEO Marc Benioff’s keynote this week was posted on…

By Danilo Masoni MILAN (Reuters) -Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House. Pharma companies’ earnings outlook is being obscured by concerns over revived “most-favored-nation” drug pricing rules in the lucrative U.S. market and potential 200% tariffs on pharma imports into the U.S. Money flooded into drugmakers’ shares during the COVID-19 pandemic but more recently there has been an exodus as investors shifted into Big Tech, leaving the…

(Reuters) -Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported on Wednesday, citing people familiar with the matter. Shares of Avidity rose 23% to $47.1. It has a market value of $4.6 billion, according to LSEG data. Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, the report said, in a move aimed at boosting the drugmaker’s pipeline of medicines targeting rare genetic disorders. The discussions were at an early stage, the report said, adding that the sources had cautioned that another suitor…

WASHINGTON (AP) — Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of its gene therapy following several patient deaths. The decision, announced late Monday, comes just days after the company rebuffed FDA regulators in an extremely unusual decision that alarmed investors and analysts. Sarepta CEO Doug Ingram said the company seeks a “productive and positive” relationship with FDA and that “maintaining that productive working relationship required this temporary suspension.” The Cambridge, Massachusetts-based company said it would “ temporarily pause all shipments” of…

WASHINGTON (AP) — Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following a brief pause requested by regulators. The Food and Drug Administration said it recommended lifting the hold for young patients with Duchenne’s muscular dystrophy who are still able to walk. Regulators had requested the pause after the deaths of two older teenagers who were taking the therapy. The FDA also said in a statement it determined that a recently reported death of an 8-year-old boy was unrelated to the therapy. Company…

CVS Health topped Wall Street expectations for the second quarter and hiked its full-year forecast again, as the health care giant continued to rally under new management from a forgettable 2024. The company said Thursday it now expects adjusted 2025 earnings to range between $6.30 and $6.40 this year after hiking the forecast to a range of up to $6.20 per share in May. Analysts have forecast annual forecast earnings of $6.12 per share, according to the data firm FactSet. In the second quarter, CVS Health reported adjusted earnings of $1.81 per share as revenue grew 8% to $98.9 billion.…

Melissa Shaw.Courtesy of Melissa Shaw Melissa Shaw became her mother’s primary caregiver after a sudden terminal cancer diagnosis. Shaw, a financial advisor, learned crucial lessons about end-of-life planning and caregiving. Her biggest lessons include the importance of Medigap, healthcare proxies, and life insurance. This as-told-to essay is based on a conversation with Melissa Shaw, a 46-year-old financial advisor in Palo Alto, California. It has been edited for length and clarity. I’ve been a financial advisor since 2011 and have worked at Teachers Insurance and Annuity Association of America, or TIAA, as a wealth management advisor for over seven years. I…

President Donald Trump at an event in New York in 2016. (Brendan Smialowski / AFP via Getty Images) The Coca-Cola Co. said Tuesday that it will launch a version of its signature drink made with American cane sugar. The announcement comes days after President Donald Trump posted on Truth Social that he had “been speaking to Coca-Cola about using REAL Cane Sugar in Coke in the United States, and they have agreed to do so.” Initially, Coca-Cola did not confirm the news. The company told NBC News last week that it appreciated Trump’s “enthusiasm for our iconic Coca-Cola brand” but…

Eli Lilly, the pharmaceutical company behind GLP-1 injection Zepbound, is working to bring its weight loss drug to the market in pill form. In an Aug. 7 earnings call, Eli Lilly CEO David Ricks told investors that the company plans to submit the drug, orforglipron, to the FDA for approval by the end of the year. Dan Skovronsky, chief scientific officer and president of Lilly Immunology, said that the company was “very pleased” with the safety and efficacy of orforglipron as seen in trials so far. Unlike injectable obesity drugs, which are peptides designed to mimic the appetite-controlling GLP-1 hormone,…